Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
Open Access
- 20 March 2015
- journal article
- Published by River Publishers in Molecular and Cellular Therapies
- Vol. 3 (1) , 2
Abstract
Technological advances allowing high throughput analyses across numerous cancer tissues have allowed much progress in understanding complex cellular signaling. In the future, the genetic landscape in cancer may have more clinical relevance than diagnosis based on tumor origin. This progress has emphasized PI3K/AKT/mTOR, among others, as a central signaling center of cancer development due to its governing control in cellular growth, survival, and metabolism. The discovery of high frequencies of mutations in the PI3K/AKT/mTOR pathway in different cancer entities has sparked interest to inhibit elements of this pathway. In acute leukemia pharmacological interruption has yet to achieve desirable efficacy as targetable downstream mutations in PI3K/AKT/mTOR are absent. Nevertheless, mutations in membrane-associated genes upstream of PI3K/AKT/mTOR are frequent in acute leukemia and are associated with aberrant activation of PI3K/AKT/mTOR thus providing a good rationale for further exploration. This review attempts to summarize key findings leading to aberrant activation and to reflect on both promises and challenges of targeting PI3K/AKT/mTOR in acute leukemia. Our emphasis lies on the insights gained through high-throughput data acquisition that open up new avenues for identifying specific subgroups of acute leukemia as ideal candidates for PI3K/AKT/mTOR targeted therapy.Keywords
This publication has 123 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemiaLeukemia, 2012
- Temporal Changes in PTEN and mTORC2 Regulation of Hematopoietic Stem Cell Self-Renewal and Leukemia SuppressionCell Stem Cell, 2012
- Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.NaLeukemia Research, 2012
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerProceedings of the National Academy of Sciences, 2009
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)Biochemical Journal, 2009
- PTEN-deficient cancers depend on PIK3CBProceedings of the National Academy of Sciences, 2008
- Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formationNature, 2008
- Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemiaNature Medicine, 2007
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994